NICE recommends Brintellix (vortioxetine) for major depressive disorder- Lundbeck

In final draft guidance, NICE has recommended Brintellix (vortioxetine), from Lundbeck, for some adults with major depressive disorder. The positive recommendation follows the submission of further evidence from the company that NICE requested in its previous draft guidance.

Following publication of the previous draft guidance on vortioxetine the company submitted further evidence on its use for adults who had not tolerated, or whose major depressive episode had not responded to two previous antidepressants. The NICE committee concluded from this evidence that vortioxetine’s effectiveness was comparable with that of other third-line antidepressants and that vortioxetine could be recommended as a cost-effective option for treating major depressive episodes in adults whose condition has responded inadequately to two antidepressants within the current episode.